



Press Release |

IBA patented its dual proton source for PET Cyclotrons

Louvain-la-Neuve, Belgium, May 20th, 2011 – IBA (Ion Beam Applications S.A.) announced today, that its dual proton source system has been exclusively patented.

The Cyclone[®] 18 Twin is the most modern version of the well-known Cyclone[®] 18/9 from IBA, greatly increasing production uptime while reducing maintenance interventions.

The Cyclone[®] Twin central region has been designed in order to host two new proton ion sources. In order to provide the IBA cyclotrons with a double life.

With more than 20 Cyclone[®] 18 Twin sold since its launch in 2007, the patent # EP 2196073 delivered in April enables IBA to offer the highest uptime and most reliable production cyclotrons.

“Those who manufacture radioisotopes have been waiting for a solution to maximize the reliability, efficiency and safety of their production,” said Yves Jongen, Chief Research Officer at IBA. *“We have recognized this need and aligned our resources to develop the most reliable solution available on the market today”*, he continued.

Thanks to this redundant ion source, the global ion source lifetime is greatly extended, the number of maintenance interventions reduced and personnel exposure is further limited. Switching to a second spare source during production is simple, fast and completely automated. The production run can be resumed without any delays.

With its 8 independent production target systems and dual proton ion source, IBA is once again pushing the limits of technology putting the emphasis on redundancy and reliability.

About IBA

IBA delivers solutions of exceptional precision in the fields of cancer diagnosis and therapy. The company also provides sterilization and ionization solutions to improve the hygiene and safety of everyday life. IBA is listed on the pan-European stock exchange EURONEXT and belongs to the BelMid index.

IBA Molecular's division is the only global provider of PET radiopharmaceuticals. We have leveraged our global expertise and innovation to maximize our customers' access to the most reliable radiopharmaceutical distribution network, the most advanced cyclotron solutions and the most novel research radionuclides. With our focus on Protecting, Enhancing and Saving Lives, we are committed to ensuring that our customers' ability to properly care for their patients is not compromised by their access to vital radiopharmaceuticals

Website: <http://www.iba-cyclotronsolutions.com>.

Contact

IBA Molecular

Peter Leitner

Sales & Marketing Director, Molecular Equipment

Cell: +32 499 98 56 69

Email : Peter.Leitner@iba-group.com